JP6951971B2 - 親水性薬物の標的化された送達 - Google Patents
親水性薬物の標的化された送達 Download PDFInfo
- Publication number
- JP6951971B2 JP6951971B2 JP2017514562A JP2017514562A JP6951971B2 JP 6951971 B2 JP6951971 B2 JP 6951971B2 JP 2017514562 A JP2017514562 A JP 2017514562A JP 2017514562 A JP2017514562 A JP 2017514562A JP 6951971 B2 JP6951971 B2 JP 6951971B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- aqueous
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1400427-9 | 2014-09-10 | ||
SE1400427 | 2014-09-10 | ||
PCT/SE2015/000055 WO2016039678A1 (en) | 2014-09-10 | 2015-09-09 | Targeted delivery of hydrophilic drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017527593A JP2017527593A (ja) | 2017-09-21 |
JP2017527593A5 JP2017527593A5 (ko) | 2018-07-05 |
JP6951971B2 true JP6951971B2 (ja) | 2021-10-20 |
Family
ID=55459328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017514562A Active JP6951971B2 (ja) | 2014-09-10 | 2015-09-09 | 親水性薬物の標的化された送達 |
Country Status (11)
Country | Link |
---|---|
US (2) | US10034838B2 (ko) |
EP (1) | EP3191138B1 (ko) |
JP (1) | JP6951971B2 (ko) |
KR (1) | KR20170054459A (ko) |
CN (1) | CN107073129B (ko) |
AU (1) | AU2015316252A1 (ko) |
CA (1) | CA2958820A1 (ko) |
EA (1) | EA033526B1 (ko) |
IL (1) | IL250637A0 (ko) |
MX (1) | MX2017003049A (ko) |
WO (1) | WO2016039678A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069423A (zh) * | 2016-03-07 | 2018-12-21 | 双键医药品股份公司 | 亲水性药物的肺部靶向递送 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
JP2002506876A (ja) * | 1998-03-18 | 2002-03-05 | ユニバーシティ テクノロジー コーポレーション | 非晶質ポリマーを含む持続放出性組成物 |
US6384081B2 (en) * | 1998-10-09 | 2002-05-07 | Charles L. Berman | Treatment of diseases of the eye characterized by the formation of metalloproteinase |
CN100341589C (zh) * | 2002-05-24 | 2007-10-10 | 血管技术国际股份公司 | 用于涂覆医用植入物的组合物和方法 |
US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
GB2415904B (en) * | 2005-02-07 | 2006-10-25 | Chiron Corp | Preparing aldesleukin for pharmaceutical use |
WO2009078756A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
CN101327190B (zh) * | 2008-07-29 | 2011-04-27 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
WO2012013609A1 (en) * | 2010-07-26 | 2012-02-02 | Bioréalités S.A.S. | Methods and compositions for liver cancer therapy |
KR101728011B1 (ko) * | 2013-01-23 | 2017-04-20 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 덱스트란 메타크릴레이트 및 생체적합성 음이온성 고분자를 포함하는 생분해성 마이크로 비드 및 이의 제조방법 |
-
2015
- 2015-09-09 WO PCT/SE2015/000055 patent/WO2016039678A1/en active Application Filing
- 2015-09-09 MX MX2017003049A patent/MX2017003049A/es unknown
- 2015-09-09 KR KR1020177009510A patent/KR20170054459A/ko unknown
- 2015-09-09 CN CN201580048892.5A patent/CN107073129B/zh active Active
- 2015-09-09 AU AU2015316252A patent/AU2015316252A1/en not_active Abandoned
- 2015-09-09 JP JP2017514562A patent/JP6951971B2/ja active Active
- 2015-09-09 EP EP15840525.8A patent/EP3191138B1/en active Active
- 2015-09-09 CA CA2958820A patent/CA2958820A1/en not_active Abandoned
- 2015-09-09 EA EA201790272A patent/EA033526B1/ru not_active IP Right Cessation
- 2015-09-09 US US15/509,875 patent/US10034838B2/en active Active
-
2017
- 2017-02-16 IL IL250637A patent/IL250637A0/en unknown
-
2018
- 2018-07-17 US US16/037,429 patent/US10973772B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107073129B (zh) | 2021-10-15 |
JP2017527593A (ja) | 2017-09-21 |
US10034838B2 (en) | 2018-07-31 |
IL250637A0 (en) | 2017-04-30 |
US10973772B2 (en) | 2021-04-13 |
EP3191138A1 (en) | 2017-07-19 |
EA201790272A1 (ru) | 2017-07-31 |
US20190046462A1 (en) | 2019-02-14 |
US20170239192A1 (en) | 2017-08-24 |
EP3191138A4 (en) | 2018-06-20 |
CN107073129A (zh) | 2017-08-18 |
EA033526B1 (ru) | 2019-10-31 |
AU2015316252A1 (en) | 2017-03-09 |
MX2017003049A (es) | 2017-05-23 |
CA2958820A1 (en) | 2016-03-17 |
KR20170054459A (ko) | 2017-05-17 |
WO2016039678A1 (en) | 2016-03-17 |
EP3191138B1 (en) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Park et al. | PEGylated PLGA nanoparticles for the improved delivery of doxorubicin | |
Shen et al. | Versatile hyaluronic acid modified AQ4N-Cu (II)-gossypol infinite coordination polymer nanoparticles: multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring | |
Johnstone et al. | Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties | |
Morsy et al. | Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers | |
Wang et al. | Supramolecularly engineered phospholipids constructed by nucleobase molecular recognition: upgraded generation of phospholipids for drug delivery | |
Kamel et al. | Inhalable dual-targeted hybrid lipid nanocore–protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells | |
Abtahi et al. | Multifunctional stimuli-responsive niosomal nanoparticles for co-delivery and co-administration of gene and bioactive compound: In vitro and in vivo studies | |
Malhotra et al. | Polymeric micelles coated with hybrid nanovesicles enhance the therapeutic potential of the reversible topoisomerase inhibitor camptothecin in a mouse model | |
WO2012104831A1 (en) | Surface-modified heavy metal nanoparticles, compositions and uses thereof | |
WO2015138992A1 (en) | Mitochondrial delivery of 3-bromopyruvate | |
MXPA06010950A (es) | Formulaciones en nano-particulas de compuestos de platino. | |
Li et al. | Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency | |
CN112933046B (zh) | 一种阿霉素前药主动载药脂质体及其制备方法和应用 | |
Xu et al. | Selective self-induced stimulus amplification prodrug platform for inhibiting multidrug resistance and lung metastasis | |
Wang et al. | Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies | |
Chi et al. | Dual-Responsive multifunctional “core–shell” magnetic nanoparticles promoting Fenton reaction for tumor ferroptosis therapy | |
Cai et al. | Aperture modulation of isoreticular metal organic frameworks for targeted antitumor drug delivery | |
de la Mata et al. | Carbosilane dendritic nanostructures, highly versatile platforms for pharmaceutical applications | |
Raut et al. | Sorafenib tosylate novel drug delivery systems: implications of nanotechnology in both approved and unapproved indications | |
JP6951971B2 (ja) | 親水性薬物の標的化された送達 | |
Zhang et al. | pH/ROS Dual-Responsive Polymer–Drug-Based Nanocarriers: Click-Reaction Preparation and Fluorescence Imaging-Guided Chemotherapy and Photodynamic Therapy | |
Gad et al. | Novel approaches of solid lipid nanoparticles as drug carrier | |
JP2019500406A (ja) | 抗癌薬の新規ナノ製剤及びその製造方法 | |
Shen et al. | Modular assembly of drug and monodisperse SPIONs for superior magnetic and T2-imaging performance | |
Yang et al. | A reversible decomposition approach for the formation of injectable, excipient-free, self-assembling nanocrystals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180528 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180528 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190507 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200225 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200313 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200317 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200515 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200519 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201106 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20210325 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210622 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210721 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210804 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210902 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210927 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6951971 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |